BS_S0175QKX
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- overall_survival_months
- 47.28
- os_event
- false
- age_years
- 1.348
- sex
- M
- race
- White
- e1_e2
- E2
- umap1_2d
- -5.881048732
- umap2_2d
- 1.841158511
- umap1_3d
- -0.638711711
- umap2_3d
- 3.880320769
- umap3_3d
- -0.441210919
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.660
- MYC_TARGETS_V1+0.600
- G2M_CHECKPOINT+0.570
- MYC_TARGETS_V2+0.500
- WNT_BETA_CATENIN_SIGNALING+0.420
- NOTCH_SIGNALING+0.410
- CHOLESTEROL_HOMEOSTASIS+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.380
- DNA_REPAIR+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.440
- INFLAMMATORY_RESPONSE-0.430
- IL6_JAK_STAT3_SIGNALING-0.360
- ANGIOGENESIS-0.350
- IL2_STAT5_SIGNALING-0.320
- APICAL_SURFACE-0.260
- COMPLEMENT-0.260
- MYOGENESIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_S0175QKX | Posterior Fossa Ependymoma | — | 0.965 |
| 2 | BS_KDSTG5YY | Posterior Fossa Ependymoma | — | 0.896 |
| 3 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.889 |
| 4 | 800E78BA-08BE-463B-ABBA-45255B48362B | — | — | 0.888 |
| 5 | BS_DS438CXE | high-grade glioma | — | 0.883 |
| 6 | 5F991EDF-3871-4111-9A04-BF6CA02648CA | — | — | 0.879 |
| 7 | SRR8392891 | — | cohortSQ2 | 0.877 |
| 8 | ERR2598226 | fetal | fetal | 0.876 |
| 9 | C3N-04155 | — | cohortSQ2 | 0.874 |
| 10 | BS_KDSTG5YY | EPN | Posterior Fossa EPN | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.660 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |